Quintiles and Quest Diagnostics rolled out Q2 Solutions, a $575 million joint venture that pairs the CRO's experience running studies with the latter company's expertise in lab tests.
Quintiles has rewired its risk-based monitoring service to include analytics technology the CRO says can better predict pressure points in clinical trials, touting its new offering as the first of its kind.
With the clinical trial community gathering for DIA 2015, eClinical tech vendors have been rolling out releases about their new tools, hires and deals. Here we round up a batch of notable news, including a new hire at Clinical Ink, deals for DocuSign and a visit to the FDA by Nextrials.
Quintiles has opened up a new, up-sized headquarters in China, toasting the country's growth as a global biopharma power and angling to play a bigger role in its continued evolution.
Quintiles, the world's largest CRO, is targeting the growing number of small and midsize biotech companies in Asia, porting its bespoke offering to the region in hopes of partnering with the continent's up-and-coming drug developers.
A group of Quintiles shareholders including the CRO's founder made about $770 million in a secondary stock offering, selling a bulk of shares back to the company and cashing in on its success.
Awaiting the closure of a wide-ranging deal with Quest Diagnostics, Quintiles is expanding its capabilities in bioanalytics, opening a new outpost in Europe for lab tests.
Quintiles' banner business came up short in the first quarter, as currency fluctuations bit into revenue and led the world's largest CRO to dial down its full-year guidance.
Quintiles is further entrenching itself in Latin America, striking a deep-rooted alliance with a research site in Buenos Aires to widen its global network of trusted partners.
Months after LabCorp acquired its rival Covance, Quintiles has signed a sweeping agreement with lab testing giant Quest Diagnostics to launch a joint venture focused on clinical trials.